NDC 12634-498

Naproxen

Naproxen

Naproxen is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Apotheca Inc.. The primary component is Naproxen.

Product ID12634-498_35b8ec82-7260-5925-e054-00144ff8d46c
NDC12634-498
Product TypeHuman Prescription Drug
Proprietary NameNaproxen
Generic NameNaproxen
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2010-02-18
Marketing CategoryANDA / ANDA
Application NumberANDA075927
Labeler NameApotheca Inc.
Substance NameNAPROXEN
Active Ingredient Strength250 mg/1
Pharm ClassesCyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 12634-498-00

10 TABLET in 1 BOTTLE (12634-498-00)
Marketing Start Date2010-02-18
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 12634-498-78 [12634049878]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-91 [12634049891]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-74 [12634049874]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-67 [12634049867]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-82 [12634049882]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-45 [12634049845]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-59 [12634049859]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-80 [12634049880]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-66 [12634049866]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-99 [12634049899]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-09 [12634049809]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-42 [12634049842]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-63 [12634049863]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-97 [12634049897]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-54 [12634049854]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-52 [12634049852]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-57 [12634049857]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-96 [12634049896]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-50 [12634049850]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-60 [12634049860]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-84 [12634049884]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-90 [12634049890]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-95 [12634049895]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-01 [12634049801]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-85 [12634049885]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-00 [12634049800]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-40 [12634049840]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-61 [12634049861]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-93 [12634049893]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-79 [12634049879]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-94 [12634049894]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-71 [12634049871]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-98 [12634049898]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-81 [12634049881]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-92 [12634049892]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

NDC 12634-498-69 [12634049869]

Naproxen TABLET
Marketing CategoryANDA
Application NumberANDA075927
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2010-02-18
Inactivation Date2020-01-31

Drug Details

Active Ingredients

IngredientStrength
NAPROXEN250 mg/1

OpenFDA Data

SPL SET ID:35b8ec82-725f-5925-e054-00144ff8d46c
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 198013
  • PHarm Class EPC
  • Nonsteroidal Anti-inflammatory Drug [EPC]
  • NUI Code
  • N0000000160
  • N0000175722
  • N0000175721
  • Pharmacological Class

    • Cyclooxygenase Inhibitors [MoA]
    • Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient]
    • Nonsteroidal Anti-inflammatory Drug [EPC]
    • Anti-Inflammatory Agents
    • Non-Steroidal [CS]

    NDC Crossover Matching brand name "Naproxen" or generic name "Naproxen"

    NDCBrand NameGeneric Name
    0054-3630NaproxenNaproxen
    0093-1005NaproxenNaproxen
    0093-1006NaproxenNaproxen
    0143-1346NaproxenNaproxen
    0143-1347NaproxenNaproxen
    0143-1348NaproxenNaproxen
    0143-9908NAPROXENnaproxen sodium
    0143-9916NAPROXENnaproxen sodium
    0179-1978NaproxenNaproxen
    0440-1852NaproxenNaproxen
    0440-7852NaproxenNaproxen
    0615-1504NaproxenNaproxen
    0615-3562NaproxenNaproxen
    0615-3563NaproxenNaproxen
    0615-7709NaproxenNaproxen
    0615-7892NaproxenNaproxen
    0615-8094NaproxenNaproxen
    10544-010NaproxenNaproxen
    10544-016NaproxenNaproxen
    10544-019NaproxenNaproxen
    10544-044NaproxenNaproxen
    10544-061NaproxenNaproxen
    10544-111NAPROXENNAPROXEN
    10544-277NaproxenNaproxen
    10544-278NaproxenNaproxen
    10544-614NAPROXENnaproxen sodium
    10544-920NaproxenNaproxen
    10544-922NaproxenNaproxen
    10544-939NaproxenNaproxen
    12634-498NaproxenNaproxen
    68071-3092NaproxenNaproxen
    68071-4006NAPROXENNAPROXEN
    68071-3029naproxennaproxen
    68071-3066naproxennaproxen
    68071-3387NaproxenNaproxen
    68071-3345NAPROXENNAPROXEN
    68071-4510NAPROXENNAPROXEN
    68071-4381NAPROXENNAPROXEN
    68134-201NaproxenNaproxen
    68151-2894NaproxenNaproxen
    68151-2609NaproxenNaproxen
    68151-2895NaproxenNaproxen
    68382-012NaproxenNaproxen
    68382-013NaproxenNaproxen
    68382-014NaproxenNaproxen
    68387-800NaproxenNaproxen
    68387-801NaproxenNaproxen
    68387-802NaproxenNaproxen
    68462-190NaproxenNaproxen
    68462-189NaproxenNaproxen

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.